Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LIPE | Q05469 | 8/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20293692 | 0.79 | LIPE (0.39) | LIPENPC1RAB9AATMMAPT | |
| SCHEMBL16339752 | 0.79 | GRM5 (0.40) | KMT2ALIPENPC1RAB9AGRM5 | |
| SCHEMBL16337053 | 0.79 | BTK (0.43) | LIPEGRM4 | |
| SCHEMBL29709486 | 0.79 | BTK (0.43) | LIPEGRM4 | |
| SCHEMBL26109550 | 0.78 | POLB (0.50) | KMT2ALIPENPC1RAB9ATP53 | |
| SCHEMBL105072 | 0.78 | DHPS (0.50) | RAB9AALDH1A1LMNABACE1 | |
| SCHEMBL2992272 | 0.78 | LIPE (0.51) | KMT2ALIPENPC1RAB9AMAPT | |
| SCHEMBL30483107 | 0.78 | ALDH1A1 (0.44) | LIPEALDH1A1LMNA | |
| SCHEMBL21929107 | 0.78 | ALDH1A1 (0.44) | LIPEALDH1A1LMNA | |
| SCHEMBL13893964 | 0.77 | MAPT (0.49) | KMT2ALIPENPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | KMT2A 372/4885LIPE 4591/4885NPC1 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.